Cargando…

Anti‐PD‐1 antibodies in metastatic uveal melanoma: a treatment option?

Uveal melanomas (UMs) are a rare form of cancer with clinical and pathological characteristics distinct from cutaneous melanomas. Ipilimumab has shown efficacy and safety in the treatment of metastatic UM. This provides a rationale for treatment with other immune checkpoint inhibitors. This is a ret...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bender, Carolin, Enk, Alexander, Gutzmer, Ralf, Hassel, Jessica C.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2017
Materias:	Clinical Cancer Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5504332/ https://www.ncbi.nlm.nih.gov/pubmed/28639409 http://dx.doi.org/10.1002/cam4.887

Ejemplares similares

Progression patterns under BRAF inhibitor treatment and treatment beyond progression in patients with metastatic melanoma
por: Hassel, Jessica C., et al.
Publicado: (2017)

S100 as Serum Tumor Marker in Advanced Uveal Melanoma
por: Salzmann, Martin, et al.
Publicado: (2023)

Systemic treatment of metastatic uveal melanoma: review of literature and future perspectives
por: Buder, Kristina, et al.
Publicado: (2013)

TCR-Directed Therapy in the Treatment of Metastatic Uveal Melanoma
por: Strobel, Sophia B., et al.
Publicado: (2022)

Medical Needs and Therapeutic Options for Melanoma Patients Resistant to Anti-PD-1-Directed Immune Checkpoint Inhibition
por: Hassel, Jessica C., et al.
Publicado: (2023)

Ipilimumab plus nivolumab for patients with metastatic uveal melanoma: a multicenter, retrospective study
por: Najjar, Yana G, et al.
Publicado: (2020)

A novel combinatorial treatment option for metastatic uveal melanoma
por: Shneor, Dudi, et al.
Publicado: (2018)

Early detection of metastatic uveal melanoma by the analysis of tumor‐specific mutations in cell‐free plasma DNA
por: Le Guin, Claudia H. D., et al.
Publicado: (2021)

Hepatic Radiotherapy in Addition to Anti-PD-1 for the Treatment of Metastatic Uveal Melanoma Patients
por: Rossi, Ernesto, et al.
Publicado: (2023)

Immunotherapies for the Treatment of Uveal Melanoma—History and Future
por: Schank, Timo E., et al.
Publicado: (2019)

Metastatic disease from uveal melanoma: treatment options and future prospects
por: Carvajal, Richard D, et al.
Publicado: (2017)

Evaluation of the modified immune prognostic index to prognosticate outcomes in metastatic uveal melanoma patients treated with immune checkpoint inhibitors
por: Sander, Michael S., et al.
Publicado: (2021)

Immune implication of an autophagy-related prognostic signature in uveal melanoma
por: Chuah, Samuel, et al.
Publicado: (2021)

Beta‐blockers exert potent anti‐tumor effects in cutaneous and uveal melanoma
por: Bustamante, Prisca, et al.
Publicado: (2019)

Comprehensive analysis of cutaneous and uveal melanoma liver metastases
por: Hoefsmit, Esmee P, et al.
Publicado: (2020)

Current and emerging treatment options for uveal melanoma
por: Pereira, Patricia Rusa, et al.
Publicado: (2013)

Immune Checkpoint Blockade for Metastatic Uveal Melanoma: Re-Induction following Resistance or Toxicity
por: Koch, Elias A. T., et al.
Publicado: (2022)

Targeting immune checkpoints in unresectable metastatic cutaneous melanoma: a systematic review and meta‐analysis of anti‐CTLA‐4 and anti‐PD‐1 agents trials
por: Yun, Seongseok, et al.
Publicado: (2016)

Tadalafil has biologic activity in human melanoma. Results of a pilot trial with Tadalafil in patients with metastatic Melanoma (TaMe)
por: Hassel, Jessica C., et al.
Publicado: (2017)

Multiregional genetic evolution of metastatic uveal melanoma
por: Rodriguez, Daniel A., et al.
Publicado: (2021)

Uveal melanoma diagnosis and current treatment options (Review)
por: Branisteanu, Daniel Constantin, et al.
Publicado: (2021)

Efficacy and safety of cosibelimab, an anti-PD-L1 antibody, in metastatic cutaneous squamous cell carcinoma
por: Clingan, Philip, et al.
Publicado: (2023)

Efficacy and safety of anti-PD1 monotherapy or in combination with ipilimumab after BRAF/MEK inhibitors in patients with BRAF mutant metastatic melanoma
por: Pires da Silva, Ines, et al.
Publicado: (2022)

Long-term follow-up of anti-PD-1 naïve patients with metastatic melanoma treated with IDO/PD-L1 targeting peptide vaccine and nivolumab
por: Lorentzen, Cathrine Lund, et al.
Publicado: (2023)

Tolerability of BRAF and MEK Inhibitors for Metastasized Melanoma after Intra-Class Switch: A Multicenter, Retrospective Study
por: Salzmann, Martin, et al.
Publicado: (2023)

Efficacy of anti-PD-1 and ipilimumab alone or in combination in acral melanoma
por: Bhave, Prachi, et al.
Publicado: (2022)

Clinical and molecular characteristics associated with response to therapeutic PD-1/PD-L1 inhibition in advanced Merkel cell carcinoma
por: Spassova, Ivelina, et al.
Publicado: (2022)

Chemosaturation with percutaneous hepatic perfusion of melphalan for metastatic uveal melanoma
por: Modi, Sachin, et al.
Publicado: (2022)

Treatment of Metastatic Uveal Melanoma: Systematic Review
por: Rodriguez-Vidal, Cristina, et al.
Publicado: (2020)

Novel treatment paradigms for metastatic uveal melanoma
por: Patel, Sapna P., et al.
Publicado: (2022)

Efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in patients with metastatic melanoma after prior anti-PD-1 therapy
por: Bowyer, S, et al.
Publicado: (2016)

The genetic evolution of metastatic uveal melanoma
por: Shain, A. Hunter, et al.
Publicado: (2019)

Minimally Invasive Treatment Options for Hepatic Uveal Melanoma Metastases
por: Sajan, Abin, et al.
Publicado: (2023)

Intermittent MEK inhibition for the treatment of metastatic uveal melanoma
por: Khan, Shaheer, et al.
Publicado: (2022)

Immune Checkpoint Blockade for Metastatic Uveal Melanoma: Patterns of Response and Survival According to the Presence of Hepatic and Extrahepatic Metastasis
por: Koch, Elias A. T., et al.
Publicado: (2021)

Ultradeep sequencing detects GNAQ and GNA11 mutations in cell-free DNA from plasma of patients with uveal melanoma
por: Metz, Claudia HD, et al.
Publicado: (2013)

The efficacy of anti‐programmed cell death protein 1 therapy among patients with metastatic acral and metastatic mucosal melanoma
por: Ogata, Dai, et al.
Publicado: (2021)

Phase II DeCOG-Study of Ipilimumab in Pretreated and Treatment-Naïve Patients with Metastatic Uveal Melanoma
por: Zimmer, Lisa, et al.
Publicado: (2015)

Tebentafusp in combination with durvalumab and/or tremelimumab in patients with metastatic cutaneous melanoma: a phase 1 study
por: Hamid, Omid, et al.
Publicado: (2023)

Real‐world survival of patients with advanced BRAF V600 mutated melanoma treated with front‐line BRAF/MEK inhibitors, anti‐PD‐1 antibodies, or nivolumab/ipilimumab
por: Moser, Justin C., et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_9g96739pmpl1thsl0du4d4qgjk